News | February 20, 2014

Leadless Pacemaker Used in Sequoia Hospital Clinical Trial

St. Jude Medical Nanostim Leadless Pacemaker EP Lab Clinical Trial

February 20, 2014 — St. Jude Medical selected Dignity Health Sequoia Hospital's Heart and Vascular Institute and Silicon Valley Cardiology to participate in a clinical trial bringing the first leadless pacemaker to the west coast.

The Nanostim Cardiac Leadless Pacemaker is smaller than a triple-A battery and is designed to be placed directly into the heart, requiring only a minimally invasive procedure. The device is not approved by the U.S. Food and Drug Administration (FDA) for use in the United States, but is commercially available and has been used successfully in Europe. Cardiologists Hardwin Mead and Rob Patrawala have undergone special training on implanting the device and are leading the clinical trial at Sequoia's Heart and Vascular Institute. The trial is St. Jude Medical sponsored and is part of the process to seek FDA approval. It aims to enroll more than 600 patients at 60 international sites.

The device has been implanted in only five other patients in the country, all east of the Mississippi River. In total, 10 to 20 patients will be a part of the trial at Sequoia. The first patient has received the device at Sequoia and is doing well.

"The actual procedure is minimally invasive and efficient,” said Mead, who performed the procedure. “There is no surgical scar and no insulated wires, which is a big advantage for the patient over a conventional pacemaker." 

"It is designed to be fully retrievable, has its own generator and battery, and can last eight to 10 years with normal use," Patrawala said.

For more information: www.sequoiahospital.org

Related Content

Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init